

IN THE CLAIMS:

1-3. (Canceled)

1 ~~4~~. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of an Mts1 protein.

2 ~~5~~. (Original) The isolated multimeric Mts1 protein complex of claim ~~4~~, having a Mw in the range of about 30 kD to about 200 kD.

3 ~~6~~. (Currently amended) The isolated multimeric Mts1 protein complex of claim ~~4~~, wherein said Mts1 protein is a wild type Mts1 protein.

4 ~~7~~. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of Mts1-dcl75.

5 ~~8~~. (Previously presented) The isolated multimeric Mts1 protein complex of claim ~~4~~, wherein said Mts1 protein is of a mammalian origin.

6 ~~9~~. (Canceled)

7 ~~10~~. (Original) A pharmaceutical composition comprising the isolated complex of claim ~~4~~, and a pharmaceutically acceptable carrier.

8 ~~11~~. (Previously presented) The pharmaceutical composition of claim ~~10~~, wherein said pharmaceutically acceptable carrier is liquid, semi-solid, or solid.

9 ~~12~~. (Previously presented) The pharmaceutical composition of claim ~~10~~, further comprising a neurotropic factor.

⁸
9 13. (Original) The pharmaceutical composition of claim 12, wherein said neurotropic factor is selected from the group consisting of bFGF, aFGF, CNTF, NGF, BDNF, GDNF, NT3, NT4/5, IGF-1 and IGF-II.

14-25. (Canceled)

10 26. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4,
wherein said Mts-1 protein is a human Mts-1 protein.

11 27. (Previously presented) The isolated multimeric Mts1 protein complex of claim 26,
wherein said human Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 1.

12 28. (Previously presented) The isolated multimeric Mts1 protein complex of claim 4,
wherein said Mts-1 protein comprises the sequence as set forth in SEQ ID NO: 2.

13 29. (Previously presented) An isolated multimeric Mts1 protein complex, comprising at least three molecules of human Mts1-del75.